Author:
Kaplan Allen,Ledford Dennis,Ashby Mark,Canvin Janice,Zazzali James L.,Conner Edward,Veith Joachim,Kamath Nikhil,Staubach Petra,Jakob Thilo,Stirling Robert G.,Kuna Piotr,Berger William,Maurer Marcus,Rosén Karin
Funder
Genentech, Inc and Novartis Pharma
Subject
Immunology,Immunology and Allergy
Reference25 articles.
1. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria;Zuberbier;Allergy,2009
2. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses;Asero;Clin Exp Dermatol,2007
3. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report;Maurer;Allergy,2011
4. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria;Staevska;J Allergy Clin Immunol,2010
5. Omalizumab (XOLAIR®). Summary of product characteristics. European Medicines Agency (EMA). Available at: http://www.ema.europa.eu. Accessed July 11, 2012.
Cited by
447 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献